Characterization and role of lentivirus-associated host proteins

Experimental Biology and Medicine

Volumn 231, Issue 3, 2006, Pages 252-263

  Kolegraff, Keli ^a   Bostik, Pavel ^a   Ansari, Aftab A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enveloped viruses; Host proteins; Lentivirus; Pathogenesis

Indexed keywords

CD28 ANTIGEN; CD86 ANTIGEN; COMPLEMENT; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL MEMBRANE; CELL STIMULATION; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFLUENZA VIRUS; LENTIVIRINAE; LIPID RAFT; MACROPHAGE; NONHUMAN; PRIMATE; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETROVIRUS INFECTION; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS PATHOGENESIS;

HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; ORTHOMYXOVIRIDAE; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33644667558     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100303     Document Type: Short Survey

References (116)

1. Kim FJ, Battini JL, Manel N, Sitbon M. Emergence of vertebrate retroviruses and envelope capture. Virology 318:183-191, 2004.
2. Briggs JA, Wilk T, Fuller SD. Do lipid rafts mediate virus assembly and pseudotyping? J Gen Virol 84:757-768, 2003.
3. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 3:1023-1040, 1990.
4. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers R. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112, 1990.
5. Nayak DP, Hui EK. The role of lipid microdomains in virus biology. Subcell Biochem 37:443-491, 2004.
6. Jayakar HR, Jeetendra E, Whitt MA. Rhabdovirus assembly and budding. Virus Res 106:117-132, 2004.
7. Mettenleiter TC. Budding events in herpesvirus morphogenesis. Virus Res 106:167-180, 2004.
8. Smith GL, Law M. The exit of vaccinia virus from infected cells. Virus Res 106:189-197, 2004.
9. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915-2931, 2002.
10. Pornillos O, Garrus JE, Sundquist WI. Mechanisms of enveloped RNA virus budding. Trends Cell Biol 12:569-579, 2002.
11. Morita E, Sundquist WI. Retrovirus budding. Annu Rev Cell Dev Biol 20:395-425, 2004.
12. Edidin M. The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct 32:257-283, 2003.
13. Horejsi V. The roles of membrane microdomains (rafts) in T cell activation. Immunol Rev 191:148-164, 2003.
14. Lescar J, Roussel A, Wien MW, Navaza J, Fuller SD, Wengler G, Rey FA. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105:137-148, 2001.
15. Bhattacharya J, Peters PJ, Clapham PR. Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles. J Virol 78:5500-5506, 2004.
16. Pelchen-Matthews A, Kramer B, Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 162:443-455, 2003.
17. gag associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J Virol 77:4805-4817, 2003.
18. Rousso I, Mixon MB, Chen BK, Kim PS. Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci U S A 97:13523-13525, 2000.
19. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74:3264-3272, 2000.
20. Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with β-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol 77:8237-8248, 2003.
21. Beausejour Y, Tremblay MJ. Envelope glycoproteins are not required for insertion of host ICAM-1 into human immunodeficiency virus type 1 and ICAM-1-bearing viruses are still infectious despite a suboptimal level of trimeric envelope proteins. Virology 324:165-172, 2004.
22. Chazal N, Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 67:226-237, 2003.
23. Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseudotyping. J Virol 75:7175-7183, 2001.
24. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 19:346-351, 1998.
25. Orentas RJ, Hildreth JE. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 9:1157-1165, 1993.
26. Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW Jr, Arthur LO, Ott DE, Lifson JD. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol 75:6173-6182, 2001.
27. Aloia RC, Tian H, Jensen FC. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A 90:5181-5185, 1993.
28. Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A 85:900-904, 1988.
29. Liao Z, Graham DR, Hildreth JE. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses 19:675-687, 2003.
30. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 74:139-145, 2000.
31. Nguyen DG, Booth A, Gould SJ, Hildreth JE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem 278:52347-52354, 2003.
32. Raposo G, Moore M, Innes D, Leijendekker R, Leigh-Brown A, Benaroch P, Geuze H. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 3:718-729, 2002.
33. Rabesandratana H, Toutant JP, Reggio H, Vidal M. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes. Blood 91:2573-2580, 1998.
34. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and a-granules. Blood 94:3791-3799, 1999.
35. Whiteside TL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer 92:209-211, 2005.
36. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92:305-311, 2005.
37. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namane A, Mecheri S. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 166:868-876, 2001.
38. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol 168:3235-3241, 2002.
39. Arnold PY, Mannie MD. Vesicles bearing MHC class II molecules mediate transfer of antigen from antigen-presenting cells to CD4+ T cells. Eur J Immunol 29:1363-1373, 1999.
40. Patel DM, Arnold PY, White GA, Nardella JP, Mannie MD. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 163:5201-5210, 1999.
41. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161-1172, 1996.
42. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569-579, 2002.
43. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt 19:3365-3374, 2000.
44. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic 3:321-330, 2002.
45. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230:125-133, 1997.
46. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230:134-144, 1997.
47. Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A 100:10592-10597, 2003.
48. Sheppard HW, Ascher MS. The relationship between AIDS and immunologic tolerance. J Acquir Immune Defic Syndr 5:143-147, 1992.
49. Sheppard HW, Ascher MS. The natural history and pathogenesis of HIV infection. Annu Rev Microbiol 46:533-564, 1992.
50. Fultz PN, McClure HM, Anderson DC, Swenson RB, Anand R, Srinivasan A. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A 83:5286-5290, 1986.
51. Bostik P, Dodd GL, Ansari AA. CD4+ T cell signaling in the natural SIV host - implications for disease pathogenesis. Front Biosci 8: s904-s912, 2003.
52. Ansari AA, Onlamoon N, Bostik P, Mayne AE, Gargano L, Pattanapanyasat K. Lessons learnt from studies of the immune characterization of naturally SIV infected sooty mangabeys. Front Biosci 8:s1030-s1050, 2003.
53. Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, Chakrabarti LA. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 72:3872-3886, 1998.
54. Letvin NL, Eaton KA, Aldrich WR, Sehgal PK, Blake BJ, Schlossman SF, King NW, Hunt RD. Acquired immunodeficiency syndrome in a colony of macaque monkeys. Proc Natl Acad Sci U S A 80:2718-2722, 1983.
55. Bechtel JT, Winant RC, Ganem D. Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol 79:4952-4964, 2005.
56. Ott DE. Potential roles of cellular proteins in HIV-1. Rev Med Virol 12:359-374, 2002.
57. Ott DE. Cellular proteins in HIV virions. Rev Med Virol 7:167-180, 1997.
58. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258, 1996.
59. Medema JP, Borst J. T cell signaling: a decision of life and death. Hum Immunol 60:403-411, 1999.
60. Frauwirth KA, Alegre ML, Thompson CB. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J Immunol 164:2987-2993, 2000.
61. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 157: 636-642, 1996.
62. Martin G, Tremblay MJ. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin Immunol 111:275-285, 2004.
63. Giguere JF, Bounou S, Paquette JS, Madrenas J, Tremblay MJ. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J Virol 78:6222-6232, 2004.
64. Giguere JF, Paquette JS, Bounou S, Cantin R, Tremblay MJ. New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1. J Immunol 169:2762-2771, 2002.
65. Schols D, Pauwels R, Desmyter J, De Clercq E. Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology 189:374-376, 1992.
66. Saarloos MN, Sullivan BL, Czerniewski MA, Parameswar KD, Spear GT. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J Virol 71:1640-1643, 1997.
67. Henderson LE, Sowder R, Copeland TD, Oroszlan S, Arthur LO, Robey WG, Fischinger PJ. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol 61:629-632, 1987.
68. Cantin R, Fortin JF, Lamontagne G, Tremblay M. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood 90:1091-1100, 1997.
69. Cantin R, Fortin JF, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 71:1922-1930, 1997.
70. Arthur LO, Bess JW Jr, Sowder RC II, Benveniste RE, Mann DL, Chermann JC, Henderson LE. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935-1938, 1992.
71. Bounou S, Dumais N, Tremblay MJ. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-κB- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription. J Biol Chem 276:6359-6369, 2001.
72. Roy J, Martin G, Giguere JF, Belanger D, Petrin M, Tremblay MJ. HIV type 1 can act as an APC upon acquisition from the host cell of peptide-loaded HLA-DR and CD86 molecules. J Immunol 174:4779-4788, 2005.
73. Rossio JL, Bess J Jr, Henderson LE, Cresswell P, Arthur LO. HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. AIDS Res Hum Retroviruses 11:1433-1439, 1995.
74. Hunter JB, Menitove JE. HLA antibodies detected by ELISA HTLV-III antibody kits. Lancet 2:397, 1985.
75. Kuhnl P, Seidl S, Holzberger G. HLA DR4 antibodies cause positive HTLV-III antibody ELISA results. Lancet 1:1222-1223, 1985.
76. Hoxie JA, Fitzharris TP, Youngbar PR, Matthews DM, Rackowski JL, Radka SF. Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol 18:39-52, 1987.
77. Benkirane M, Blanc-Zouaoui D, Hirn M, Devaux C. Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol 68:6332-6339, 1994.
78. Castellino F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum Immunol 54: 159-169, 1997.
79. Holling TM, Schooten E, van Den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol 65:282-290, 2004.
80. Al-Daccak R, Mooney N, Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 16:108-113, 2004.
81. Cantin R, Fortin JF, Tremblay M. The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. Virology 218:372-381, 1996.
82. Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256-259, 1987.
83. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767, 1984.
84. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768, 1984.
85. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC, Montagnier L. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 225:59-63, 1984.
86. McDougal JS, Maddon PJ, Dalgleish AG, Clapham PR, Littman DR, Godfrey M, Maddon DE, Chess L, Weiss RA, Axel R. The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol 51(Pt 2):703-711, 1986.
87. Kamp W, Breij EC, Nottet HS, Berk MB. Interactions between major histocompatibility complex class II surface expression and HIV: implications for pathogenesis. Eur J Clin Invest 31:984-991, 2001.
88. Guo MM, Hildreth JE. HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses 11:1007-1013, 1995.
89. +-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76:1004-1014, 2002.
90. Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol 71:3444-3450, 1997.
91. Gomez MB, Hildreth JE. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol 69:4628-4632, 1995.
92. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51:813-819, 1987.
93. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 9:27-66, 1991.
94. Paquette JS, Fortin JF, Blanchard L, Tremblay MJ. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol 72:9329-9336, 1998.
95. Hioe CE, Chien PC Jr, Lu C, Springer TA, Wang XH, Bandres J, Tuen M. LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 75:1077-1082, 2001.
96. Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71:3588-3596, 1997.
97. Fortin JF, Cantin R, Tremblay MJ. T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 72:2105-2112, 1998.
98. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78: 12062-12065, 2004.
99. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol 41:1089-1098, 2004.
100. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78(Pt 8):1907-1911, 1997.
101. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182:501-509, 1995.
102. Saifuddin M, Ghassemi M, Patki C, Parker CJ, Spear GT. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses 10:829-837, 1994.
103. Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 25:285-290, 1995.
104. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155:4376-4381, 1995.
105. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 95:7544-7549, 1998.
106. Krauss O, Hollinshead R, Hollinshead M, Smith GL. An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol 83:2347-2359, 2002.
107. Sullivan BL, Knopoff EJ, Saifuddin M, Takefman DM, Saarloos MN, Sha BE, Spear GT. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 157:1791-1798, 1996.
108. Bounou S, Giguere JF, Cantin R, Gilbert C, Imbeault M, Martin G, Tremblay MJ. The importance of virus-associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context. FASEB J 18:1294-1296, 2004.
109. + T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1. J Virol 75:1152-1164, 2001.
110. Lawn SD, Butera ST. Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J Virol 74:10256-10259, 2000.
111. Frank I, Kacani L, Stoiber H, Stossel H, Spruth M, Steindl F, Romani N, Dierich MP. Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. J Virol 73:3449-3454, 1999.
112. Chelius D, Huhmer AF, Shieh CH, Lehmberg E, Traina JA, Slattery TK, Pungor E Jr. Analysis of the adenovirus type 5 proteome by liquid chromatography and tandem mass spectrometry methods. J Proteome Res 1:501-513, 2002.
113. Johannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, Illanes D, Sarracino D, Kieff E. Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101:16286-16291, 2004.
114. Kattenhorn LM, Mills R, Wagner M, Lomsadze A, Makeev V, Borodovsky M, Ploegh HL, Kessler BM. Identification of proteins associated with murine cytomegalovirus virions. J Virol 78:11187-11197, 2004.
115. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG II, Rodland K, Wiley S, Britt W, Shenk T, Smith RD, Nelson JA. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960-10966, 2004.
116. Zhu FX, Chong JM, Wu L, Yuan Y. Virion proteins of Kaposi's sarcoma-associated herpesvirus. J Virol 79:800-811, 2005.